GlassScriptPhysician profile
Eric W Gold
NPI 1043326119
$5,595.19
in general payments reported to CMS, 2019-2025
22 companies · $1,459 in 2025
The $1,459 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $499 · 2022: $982 · 2023: $1,163 · 2024: $1,491 · 2025: $1,459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,906 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,905.77 |
| Education | $207.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,613.24 | 2021-2025 | |
| Janssen Biotech, INC. | $1,298.64 | 2021-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $591.95 | 2021-2025 | |
| Galderma Laboratories, L.P. | $488.20 | 2021-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $366.33 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $265.45 | 2024 | Zoryve |
| Genzyme Corporation | $147.80 | 2021-2025 | |
| Lilly USA, LLC | $143.15 | 2021-2024 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $120.40 | 2021-2025 | Libtayo, Dupixent |
| Ucb, INC. | $99.44 | 2022-2025 | Cimzia, Bimzelx |
| Sun Pharmaceutical Industries INC. | $72.54 | 2021-2022 | |
| Incyte Corporation | $66.00 | 2022-2025 | Opzelura |
| Pfizer INC. | $60.49 | 2023-2025 | |
| Amgen INC. | $58.91 | 2022-2025 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.73 | 2023-2025 | Spevigo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.44 | 2021-2025 | Cabtreo, Jublia |
| Alexion Pharmaceuticals, INC. | $29.96 | 2025 | Koselugo |
| Dermavant Sciences, INC. | $28.17 | 2023 | Vtama |
| Leo Pharma INC. | $26.63 | 2025 | Anzupgo |
| Genentech USA, INC. | $19.01 | 2023 | Erivedge |
| Helsinn Therapeutics (U.S.), INC. | $18.93 | 2024 | Valchlor |
| Organon LLC | $11.78 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.